BRAF and central nervous system cancer: Since BRAF V600E mutant gliomas often develop acquired resistance to FDA approved small molecule inhibitor [32], our PDOX model would be a powerful tool to conduct pre-clinical testing of new BRAF V600E targeting inhibitors.